glp-1 therapy gonzales news november 6 2025 Nutritional priorities to support GLP-1 for obesity: A Enrollment of Females in Randomized

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial Multi-receptor agonists that target the glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) receptors may improve outcomes in type 2 diabetes because this condition is linked to hyperglycemia and obesity

So then taking a GLP-1 for the rest of their life may not be something that they want to do. If a patient wants a one-time treatment, surgery is the best approach because you get it once and the results last for at least a decade, Chhabra adds

Baseline labs create a reference point to distinguish between dose adjustments driven by weight loss versus changes related to immune or medication effects

Mendes de Oliveira E, Keogh JM, Talbot F, et al

The problem was the side effects associated, particularly with GLP-1, are what we call peak to trough: so the difference between the highest amount of drug and the lowest and then going back up again to the highest caused by this twice-a-day dosingwhich you can imagine someone bouncing around maybe two to three times, the drug at peak, then trough, causes a lot of GI distress

At Functional Health Center, our integrated approach is designed to optimize these outcomes